Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign

by divibasicbldev | Aug 2, 2022 | Press Releases

Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash Grab Board Unanimously Recommends Stockholders to Sign, Date and Return GOLD Consent Revocation Card MIAMI...

Pasithea Therapeutics Awarded a Drug Development Research Grant

by divibasicbldev | Jul 14, 2022 | Press Releases

— AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction —- Provides approximately U.S. $694,000 of non-dilutive funding — MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp....

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

by divibasicbldev | Jun 23, 2022 | Press Releases

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for...

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

by divibasicbldev | Jun 22, 2022 | Press Releases

– Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases — Expands pipeline across Pasithea’s core therapeutic areas to drive enhanced growth —...

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

by divibasicbldev | Apr 14, 2022 | Press Releases

MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for...